Vericel Competitors

Neurocrine Biosciences (NASDAQ:NBIX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Valuation & Earnings

This table compares Neurocrine Biosciences and Vericel's top-line revenue, earnings per share (EPS) and valuation.

Neurocrine Biosciences has higher revenue and earnings than Vericel. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Neurocrine Biosciences and Vericel, as provided by MarketBeat.

Neurocrine Biosciences currently has a consensus price target of $128.7222, suggesting a potential upside of 35.14%. Vericel has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Given Neurocrine Biosciences' higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Vericel.

Profitability

This table compares Neurocrine Biosciences and Vericel's net margins, return on equity and return on assets.

Volatility & Risk

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 4.3% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Vericel on 10 of the 13 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Vericel and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

CRISPR Therapeutics has higher revenue and earnings than Vericel. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

Insider and Institutional Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vericel and CRISPR Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vericel and CRISPR Therapeutics, as reported by MarketBeat.

Vericel presently has a consensus target price of $49.00, indicating a potential downside of 15.00%. CRISPR Therapeutics has a consensus target price of $158.80, indicating a potential upside of 35.14%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Vericel.

Summary

CRISPR Therapeutics beats Vericel on 8 of the 14 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Vericel and Fate Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 4.3% of Vericel shares are held by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vericel and Fate Therapeutics, as reported by MarketBeat.

Vericel presently has a consensus target price of $49.00, suggesting a potential downside of 15.00%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 32.15%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Vericel.

Risk & Volatility

Vericel has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vericel and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Vericel has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Risk and Volatility

Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Institutional and Insider Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 79.8% of Acceleron Pharma shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Comparatively, 2.5% of Acceleron Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vericel and Acceleron Pharma's revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vericel and Acceleron Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vericel and Acceleron Pharma, as provided by MarketBeat.com.

Vericel presently has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Acceleron Pharma has a consensus price target of $148.2143, suggesting a potential upside of 19.50%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Acceleron Pharma is more favorable than Vericel.

Summary

Vericel beats Acceleron Pharma on 9 of the 15 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

Twist Bioscience has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Institutional and Insider Ownership

87.9% of Twist Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by insiders. Comparatively, 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Twist Bioscience and Vericel, as provided by MarketBeat.com.

Twist Bioscience presently has a consensus price target of $137.50, suggesting a potential downside of 0.56%. Vericel has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Vericel.

Profitability

This table compares Twist Bioscience and Vericel's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Twist Bioscience and Vericel's gross revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Twist Bioscience on 10 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Denali Therapeutics and Vericel's gross revenue, earnings per share (EPS) and valuation.

Vericel has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Denali Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and Vericel's net margins, return on equity and return on assets.

Institutional & Insider Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Comparatively, 4.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Denali Therapeutics and Vericel, as provided by MarketBeat.

Denali Therapeutics currently has a consensus price target of $75.8571, indicating a potential upside of 39.60%. Vericel has a consensus price target of $49.00, indicating a potential downside of 15.00%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than Vericel.

Summary

Vericel beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.